Reena Rao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7534973/publications.pdf

Version: 2024-02-01

623734 839539 20 620 14 18 citations h-index g-index papers 20 20 20 731 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. American Journal of Physiology - Renal Physiology, 2005, 288, F642-F649.	2.7	113
2	Hypertonic Stress Activates Glycogen Synthase Kinase 3β-mediated Apoptosis of Renal Medullary Interstitial Cells, Suppressing an NFκB-driven Cyclooxygenase-2-dependent Survival Pathway. Journal of Biological Chemistry, 2004, 279, 3949-3955.	3.4	80
3	GSK3 \hat{l}^2 Mediates Renal Response to Vasopressin by Modulating Adenylate Cyclase Activity. Journal of the American Society of Nephrology: JASN, 2010, 21, 428-437.	6.1	71
4	Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia/reperfusion in mice. DMM Disease Models and Mechanisms, 2015, 8, 931-40.	2.4	50
5	Specific deletion of glycogen synthase kinase- $3\hat{l}^2$ in the renal proximal tubule protects against acute nephrotoxic injury in mice. Kidney International, 2012, 82, 1000-1009.	5.2	47
6	Glycogen synthase kinase- $3\hat{l}^2$ promotes cyst expansion in polycystic kidney disease. Kidney International, 2015, 87, 1164-1175.	5.2	39
7	Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy. Oncogene, 2020, 39, 1231-1245.	5.9	31
8	Glycogen synthase kinase $3\hat{l}_{\pm}$ regulates urine concentrating mechanism in mice. American Journal of Physiology - Renal Physiology, 2015, 308, F650-F660.	2.7	26
9	Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2–Dependent Mechanism in Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2020, 31, 1697-1710.	6.1	26
10	Glycogen synthase kinase-3 regulation of urinary concentrating ability. Current Opinion in Nephrology and Hypertension, 2012, 21, 541-546.	2.0	25
11	Glycogen synthase kinaseâ€3β inhibits tubular regeneration in acute kidney injury by a FoxM1â€dependent mechanism. FASEB Journal, 2020, 34, 13597-13608.	0.5	20
12	The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease. Cell Death and Disease, 2021, 12, 947.	6.3	20
13	Enhancing Nephrology Career Interest through the ASN Kidney TREKS Program. Journal of the American Society of Nephrology: JASN, 2016, 27, 1604-1607.	6.1	19
14	MCP-1 promotes detrimental cardiac physiology, pulmonary edema, and death in the <i>cpk</i> model of polycystic kidney disease. American Journal of Physiology - Renal Physiology, 2019, 317, F343-F360.	2.7	19
15	A cAMP and CREB-mediated feed-forward mechanism regulates GSK3 $<$ b $>$ $\hat{l}^2 <$ /b $>$ in polycystic kidney disease. Journal of Molecular Cell Biology, 2016, 8, 464-476.	3.3	16
16	Glycogen Synthase Kinase-3 Signaling in Acute Kidney Injury. Nephron, 2020, 144, 609-612.	1.8	10
17	Integrin \hat{l}^21 Promotes Pancreatic Tumor Growth by Upregulating Kindlin-2 and TGF- \hat{l}^2 Receptor-2. International Journal of Molecular Sciences, 2021, 22, 10599.	4.1	7
18	Vasopressin Receptor Type-2 Mediated Signaling in Renal Cell Carcinoma Stimulates Stromal Fibroblast Activation. International Journal of Molecular Sciences, 2022, 23, 7601.	4.1	1

#	Article	IF	CITATIONS
19	Glycogen Synthase Kinase 3 Inhibition Improves Insulin Stimulated Glucose Metabolismin High Fat Fed C57/BL6J Mice. FASEB Journal, 2007, 21, A832.	0.5	0
20	Glycogen Synthase Kinaseâ€3 Inhibition Reduces Renal Cystogenesis in Polycystic Kidney Disease. FASEB Journal, 2013, 27, 1115.20.	0.5	0